Gravity Analytica

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

DCGO 12.18.2024

Full Press Release SEC Filings Our DCGO Tweets

About Gravity Analytica

Recent Filings

NEW YORK--(BUSINESS WIRE)--Dec. 18, 2024--DocGo Inc.(Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership withSHL Telemedicine(NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device acrossDocGomobile health care units. This expanded collaboration, initially launched in theNew York-New Jerseyarea, will now bring advanced cardiovascular diagnostics to patients’ homes and underserved communities in additional markets across the country.

According to theJournal of the American College of Cardiology, 46% ofU.S.counties do not have any cardiologists¹, highlighting the urgent need for accessible cardiovascular care. SHL Telemedicine’s SmartHeart®, a cutting-edge ECG device enabling high-quality 12-lead ECG performance anytime and anywhere, enhances patient care by eliminating the need for traditional clinic visits for essential cardiovascular screenings. With cardiologist-reviewed results available promptly, this innovation improves patient outcomes, especially for those in areas lacking cardiologists or access to healthcare facilities. This helps to eliminate many of the traditional obstacles that have discouraged people from engaging with cardiovascular healthcare providers.

“This partnership transforms homes and mobile health units into cutting-edge diagnostic hubs, empowering patients with convenient, high-quality care wherever they are,” saidLee Bienstock, CEO ofDocGo. “Incorporating SmartHeart® into home visits helps reduce barriers to cardiovascular care, while enabling early intervention and preventing costly emergency room visits.”

The partnership expansion also represents DocGo’s continued innovation in delivering scalable, patient-centric healthcare solutions that help improve outcomes while lowering overall costs.

“We are proud to extend our partnership withDocGoto provide accessible, high-quality cardiovascular diagnostics that help patients achieve better health outcomes while addressing the nation’s pressing need for equitable healthcare access,” saidDavid Arnon, CEO ofSHL Telemedicine.

The first phase of this partnership expansion will focus onCalifornia, whereDocGois actively addressing healthcare access challenges in underserved areas. By equipping mobile health vehicles with SmartHeart® technology,DocGowill provide critical cardiovascular diagnostics to rural communities and healthcare deserts.

AboutDocGo

DocGois leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services.DocGois helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it.DocGo'sproprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. WithMobile Health,DocGoempowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services,DocGois bridging the gap between physical and virtual care. For more information, please visitwww.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visitwww.proactivecarenow.com.

AboutSHL Telemedicine

SHL Telemedicineis engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users who use SmartHeart for personal use and to the healthcare community.SHL Telemedicineoffers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on theSIX Swiss Exchange(SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on theNasdaq Stock Exchange(SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website atwww.shl-telemedicine.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the Company’s plans, strategies, outcomes, and prospects, both business and financial, including the Company’s expanded partnership withSHL Telemedicine, the expected benefits of such partnership and the expected benefits of SmartHeart® devices. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions. Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: the Company’s ability to successfully implement its business strategy, including with respect to its partnership withSHL Telemedicineand the use of SmartHeart® devices; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; and other risk factors included in the Company’s filings with theSecurities and Exchange Commission. The forward-looking statements made in this press release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law.

¹https://www.forbes.com/sites/brucelee/2024/08/19/cardiology-deserts-46-of-us-counties-do-not-have-any-cardiologists/

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241218295511/en/

Media:Tommy MearaMoxie Strategies718-309-3506tommy@moxiestrategies.com

Investors:Mike ColeDocGo949-444-1341mike.cole@docgo.com ir@docgo.com

Source:DocGo Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

DCGO 12.18.2024

About Gravity Analytica

Recent News

Recent Filings